News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
OptiDX: An AI-Powered Optical Tool for Fluorescence-Guided Oncological Surgery
Feredun Azari, M.D., Sardar Azari, and Sunil Singhal, M.D., co-invented OptiDx, an AI-powered optical tool for fluorescence-guided oncological surgery.
Penn Spinout Interius BioTherapeutics Is Developing Tools to Perform Cell and Gene Engineering Directly in the Human Body
The hope is that this new technology could simplify the process of CAR-T cell therapy and make gene therapy widely available as a one-time injection to a much larger number of patients.
NCI Grant for New Cancer Telehealth Research Center of Excellence
The University of Pennsylvania (Penn) Telehealth Research Center in Cancer Care (Penn TRACE) will become one of four NCI Telehealth Research Centers of Excellence.
Pennovation Accelerator’s 2022 Pitch Day
The Pennovation Accelerator, an annual six week program that teaches local startups about business development, held their fifth annual Pitch Day at the Pennovation Center.
Announcing The Penn Institute for RNA Innovation
The Penn Institute for RNA Innovation is a new institute dedicated to the understanding and development of all aspects of RNA from basic to translational science.
SchoolSims Named One of 100 Fastest Growing Companies in Philadelphia Region
SchoolSims is an education company that offers technology-enhanced immersive learning solutions to leadership development for educational and other organizations.
Katie Reuther on The Future of Penn Health-Tech and Penn’s Thriving Innovation Ecosystem
Penn Health-Tech is well known for turning innovative ideas across the health system into useful technologies and products that solve problems and advance health care.
Penn Spinout Verismo Therapeutics Announces Submission of Investigational New Drug Application to the FDA for KIR-CAR T-cell Immunotherapy Candidate
Pending regulatory approval, Verismo plans to use the drug in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma.
Penn Gene-Editing Spinout iEcure Receives Rare Pediatric Disease Designation from FDA for Lead Drug Candidate
iEcure is developing the new drug candidate, GTP-506, as a treatment for a rare genetic condition caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia.
Meet Our 2021/2022 PCI Fellows Graduates
Our PCI Fellows graduates are thriving in careers in IP law, mechanical engineering, life sciences investment, and more.